Regeneron Pharmaceuticals Inc. sell Bank of America Co.
Summary
This prediction ended on 13.04.25 with a price of €494.90. Bank_of_America_Co_ correctly predicted massive losses of -41.86% for Regeneron Pharmaceuticals Inc.. Bank_of_America_Co_ has a follow-up prediction for Regeneron Pharmaceuticals Inc. where he still thinks Regeneron Pharmaceuticals Inc. is a Sell. A total of €0.84 was paid as dividends for this prediction. Bank_of_America_Co_ has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | 3.320% | 3.320% | -4.010% |
| iShares Core DAX® | 3.002% | 4.755% | 23.700% |
| iShares Nasdaq 100 | 2.966% | 0.363% | 8.027% |
| iShares Nikkei 225® | 5.606% | 4.528% | 20.313% |
| iShares S&P 500 | 2.312% | 1.811% | 5.451% |
Comments by Bank_of_America_Co_ for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
In the thread Trading Regeneron Pharmaceuticals Inc.
Current prediction by Bank_of_America_Co_ for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
17.04.25
17.04.26
09.01.26
Stopped prediction by Bank_of_America_Co_ for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
07.01.26
07.01.27
09.01.26
Regeneron Pharmaceuticals Inc.
29.03.23
29.03.24
30.03.24

